Weekly Analysts’ Ratings Changes for Enovis (ENOV)

Several analysts have recently updated their ratings and price targets for Enovis (NYSE: ENOV):

• 8/17/2026 – Enovis had its price target lowered by Canaccord Genuity Group Inc. from $50.00 to $45.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/7/2026 – Enovis had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $30.00 price target on the stock.
• 8/7/2026 – Enovis had its price target lowered by Wells Fargo & Company from $40.00 to $39.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Enovis had its price target raised by BTIG Research from $39.00 to $40.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Enovis was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/28/2026 – Enovis had its “buy” rating reaffirmed by UBS Group AG. They now have a $51.00 price target on the stock, up from $50.00.
• 7/28/2026 – Enovis had its “buy” rating reaffirmed by UBS Group AG. They now have a $51.00 price target on the stock, up from $50.00.
• 7/21/2026 – Enovis was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/8/2026 – Enovis is now covered by BMO Capital Markets. They set an “outperform” rating and a $29.00 price target on the stock.
• 7/8/2026 – Enovis had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/8/2026 – Enovis was upgraded by BMO Capital Markets to “strong-buy”.
• 7/6/2026 – Enovis was given a new $32.00 price target by Evercore Inc.
• 7/6/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/30/2026 – Enovis was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/28/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Transactions at Enovis

In other news, insider Oliver Engert bought 1,200 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have acquired a total of 4,200 shares of company stock valued at $92,084 in the last three months. Corporate insiders own 2.90% of the company’s stock.

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.